原发性醛固酮增多症无创定位诊断的新进展  

Recent developments in non-invasive localization diagnosis of primary aldosteronism

作　　者：徐成伟 张尧[1] XU Chengwei;ZHANG Yao(Department of Urology,First Affiliated Hospital of Chongqing Medical University,Chongqing,400016,China)

机构地区：[1]重庆医科大学附属第一医院泌尿外科,重庆400016

出　　处：《临床泌尿外科杂志》2025年第1期86-90,97,共6页Journal of Clinical Urology

摘　　要：原发性醛固酮增多症(primary aldosteronism,PA)是继发性高血压最常见的病因之一。高血压对靶器官的直接损害可能导致肾脏和心血管系统等不良后果。准确的定位诊断对于选择适当的治疗方案至关重要。目前临床上广泛采用肾上腺静脉采血(adrenal vein sampling,AVS)作为PA定位诊断的最佳方式。然而,AVS存在相应的局限性,如有创性、价格昂贵、技术要求高等。因此无创定位诊断在PA的诊疗过程中有望得到更广泛的应用。本综述将探讨无创定位诊断在PA诊断、治疗管理和预后评估中的应用。Primary aldosteronism(PA)stands as one of the most prevalent etiologies of secondary hypertension.The direct impact of hypertension on target organs can result in adverse outcomes within the renal and cardiovascular systems.Accurate localization diagnosis plays a pivotal role in determining appropriate treatment modalities.Currently,adrenal vein sampling(AVS)is widely adopted as the gold standard for localizing PA.However,AVS is encumbered by inherent limitations including invasiveness,high cost,and technical intricacies.Consequently,non-invasive localization diagnosis is poised to gain broader utility in the diagnosis and therapy of PA.This review aims to delve into the application of non-invasive localization diagnosis in the diagnostic,therapeutic management,and prognostic evaluation of PA.

关 键 词：原发性醛固酮增多症 分型诊断 核素分子成像 

分 类 号：R586.2[医药卫生—内分泌]